SCHEMBL1934559

SCHEMBL1934559

Cc1cc(CCC(=O)c2ccc(OC(F)(F)F)cc2)cc(C)c1OC(C)(C)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 8/20 0.43
PPARA Q07869 8/20 0.43
PPARG P37231 7/20 0.43
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
HDAC3 O15379 3/20 0.36
HDAC4 P56524 3/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC7 Q8WUI4 3/20 0.36
HDAC2 Q92769 3/20 0.36
HDAC10 Q969S8 3/20 0.36
HDAC11 Q96DB2 3/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1935430 0.88 PPARA (0.55) PPARDPPARAPPARG
SCHEMBL2153233 0.88 PPARA (0.45) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL3512485 0.87 PPARD (0.45) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL1934851 0.82 NPC1 (0.44) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL3513426 0.81 NPC1 (0.46) NPC1RAB9AHRH3EPHX2NR1H4
SCHEMBL1934897 0.78 NPC1 (0.56) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL1935077 0.77 PPARG (0.44) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL1934438 0.77 FFAR4 (0.45) PPARDPPARAPPARGNPC1RAB9A
SCHEMBL1935387 0.77 PPARD (0.46) PPARDPPARAPPARG
SCHEMBL3512404 0.77 PPARD (0.52) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011080276-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A DPP-4 INHIBITOR AND A 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE GENFIT (FR) 2011-07-07 WO claimed
US-20200384105-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2020-12-10 US disclosed
US-20200384105-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2020-12-10 US disclosed
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2020-07-28 US disclosed
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2020-07-28 US disclosed
US-20190275146-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2019-09-12 US disclosed
US-20190275146-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2019-09-12 US disclosed
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2019-07-16 US disclosed
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2019-07-16 US disclosed
US-20180280328-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2018-10-04 US disclosed
US-20120252725-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2012-10-04 US disclosed
US-20120252725-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2012-10-04 US disclosed
EP-2504005-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS Genfit (FR) 2012-10-03 EP disclosed
US-8188148-B2 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof GENFIT (FR) 2012-05-29 US disclosed
US-8188148-B2 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof GENFIT (FR) 2012-05-29 US disclosed
WO-2011080276-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A DPP-4 INHIBITOR AND A 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE GENFIT (FR) 2011-07-07 WO disclosed
WO-2011064350-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2011-06-03 WO disclosed
US-20100286276-A1 Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof GENFIT (FR) 2010-11-11 US disclosed
US-20100286276-A1 Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof GENFIT (FR) 2010-11-11 US disclosed
WO-2007147880-A1 SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF GENFIT (FR) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190275146-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARD 94/4885PPARA 65/4885PPARG 119/4885
US-20180280328-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARD 94/4885PPARA 65/4885PPARG 119/4885
US-20200384105-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARD 94/4885PPARA 65/4885PPARG 119/4885
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARD 94/4885PPARA 65/4885PPARG 119/4885
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARD 94/4885PPARA 65/4885PPARG 119/4885
US-20120252725-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT1, GOT2 PPARD 349/4885PPARA 251/4885PPARG 315/4885
US-20100286276-A1 Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof DPP3, DPP8, DPP4 PPARD 9/4885PPARA 11/4885PPARG 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.